Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer, and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.

Biotechnology

Provectus Biopharmaceuticals

Tim Scott

Heather Raines

Eric Wachter

Bruce Horowitz

The Leadership Team at Provectus Biopharmaceuticals is responsible for strategic decision-making and overall direction of the company, focusing on advancing innovative therapies for cancer treatment. This team, comprising key executives including the CEO, COO, CTO, and CFO, collaborates to drive the development of investigational drugs like PV-10, manage financial resources, and ensure operational excellence in bringing new oncology therapies to market.

Leadership Team

About

Team members

Other teams at Provectus Biopharmaceuticals

Scientific Advisors